Literature DB >> 18542953

Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.

Giovanni Lucignani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18542953     DOI： 10.1007/s00259-008-0856-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

Review 1.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

Review 2.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

Review 3.  Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Authors:  Michael R Zalutsky; David A Reardon; Oscar R Pozzi; Ganesan Vaidyanathan; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2007-05-11       Impact factor: 2.408

Review 4.  Current status and perspectives in alpha radioimmunotherapy.

Authors:  M Chérel; F Davodeau; F Kraeber-Bodéré; J F Chatal
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-12       Impact factor: 2.346

5.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Authors:  Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.

Authors:  Emma Y Song; Chang F Qu; Syed M A Rizvi; Chand Raja; Julia Beretov; Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer; Alan Perkins; Barry J Allen
Journal:  Cancer Biol Ther       Date:  2007-10-08       Impact factor: 4.742

7.  Targeted alpha particle immunotherapy for myeloid leukemia.

Authors:  Joseph G Jurcic; Steven M Larson; George Sgouros; Michael R McDevitt; Ronald D Finn; Chaitanya R Divgi; Ase M Ballangrud; Klaus A Hamacher; Dangshe Ma; John L Humm; Martin W Brechbiel; Roger Molinet; David A Scheinberg
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Authors:  Michael R Zalutsky; David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; Terence Z Wong; Darell D Bigner
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

9.  Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.

Authors:  Hyun-Soon Chong; Xiang Ma; Thien Le; Baidoo Kwamena; Diane E Milenic; Erik D Brady; Hyun A Song; Martin W Brechbiel
Journal:  J Med Chem       Date:  2007-12-07       Impact factor: 7.446

10.  Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

Authors:  Stig Palm; Tom Bäck; Ingela Claesson; Anna Danielsson; Jörgen Elgqvist; Sofia Frost; Ragnar Hultborn; Holger Jensen; Sture Lindegren; Lars Jacobsson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-01       Impact factor: 7.038
View more
  6 in total

1.  A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Authors:  John M Akudugu; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-04-14       Impact factor: 2.408

2.  Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Nucl Med Biol       Date:  2010-02       Impact factor: 2.408

Review 3.  Unconventional nuclides for radiopharmaceuticals.

Authors:  Jason P Holland; Matthew J Williamson; Jason S Lewis
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

Review 4.  Molecular targeted α-particle therapy for oncologic applications.

Authors:  Thaddeus J Wadas; Darpan N Pandya; Kiran Kumar Solingapuram Sai; Akiva Mintz
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

5.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

Review 6.  Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Authors:  Jin Su Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-01-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.